POLYMED · NSE
Poly Medicure Limited
₹1,635.7
-2.09% (-₹34.9)
Prev. close
₹1,670.6
Volume
37,535
Delivery %
46.3%
As of
20 Nov 2026
Price history
Analyst sentiment
No analyst stances in this range
0 analyst stances · last 90 days · one per analyst
Try a wider range.
Explore by date range →Analyst opinions
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Bullish on Poly Medicure for the near term, targeting ₹1,900 and ₹1,950, with a stop loss at ₹1,665. The stock is showin…” | Vishnu Kant UpadhyayMaster Capital Services | Poly Medicure | MISS | |
| “Recommends buying Polymed (CMP: 1810) with a target of 1890 and a stop-loss at 1744. The stock is attempting to build a …” | Anand JamesGeojit Investments Limited | Polymed | MISS | |
| “Recommends buying Poly Medicure at ₹2,045 with a target of ₹2,150 and a stop loss at ₹2,000, for a 1-week timeframe. The…” | Nagaraj ShettiHDFC Securities | Poly Medicure Ltd | MISS | |
| “Recommends buying Poly Medicure at ₹2775, targeting ₹2970 with a stop-loss at ₹2670. The stock delivered a strong bullis…” | Sumeet BagadiaChoice Equity Broking | Poly Medicure Ltd | MISS | |
| “LKP Research recommends buying Poly Medicure with a target price of ₹2,900. The call implies a bullish outlook on the st…” | LKP Securities AnalysisLKP Securities | Poly Medicure Ltd | MISS | |
| “Recommends buying Poly Medicure at ₹2,320.30, targeting ₹2,483 with a stop loss at ₹2,239, as a breakout stock for today…” | Sumeet BagadiaChoice Equity Broking | Poly Medicure Ltd | PENDING | |
| “Bullish on Poly Medicure Ltd, recommending a buy at ₹2790.45 with a stop loss at ₹2680 and a target price of ₹2985. The …” | Sumeet BagadiaChoice Equity Broking | Poly Medicure Ltd | MISS | |
| “Recommends buying Poly Medicure at ₹2,524.75 for a target of ₹2,666, with a stop loss at ₹2,436. This is highlighted as …” | Sumeet BagadiaChoice Equity Broking | Poly Medicure Ltd | PENDING | |
| “Recommends buying Poly Medicure at ₹2,573, targeting ₹2,800, with a stop loss at ₹2,500 for intraday trading on Wednesda…” | Vaishali ParekhPrabhudas Lilladher | Poly Medicure Ltd | PENDING |
Fundamentals
About Poly Medicure Limited
Poly Medicure Limited engages in the manufacture and sale of medical devices in India and internationally. The company offers infusion therapy products, including I.V Infusion set, extension lines, needle free connector, I.V flow regulator extension set, burette set, three way stop cock, vial access spike, transfer spike, orburator, polyflush, maifolds, polyswab, and arterial blood collection; critical care products, including vial access spikes, arterial cannula, mini mid lines over the wire, extension line, enteral connector, central venous catheters, and huber needle; dialysis and renal care products, comprising peritoneal dialysis set, haemocent, standard and safety fistula needle, dialyzer, bloodlines and dialysis system. It also provides cardiology products PTFE wire, inflation device, Y-connector, manifold, introducer, IV Cannula, hydrophilic wire, guiding catheter, drug eluting stent, PTCA balloon dilation catheter, diagnostic catheter, and electrocardiograph electrodes; vaccular access products; oncology products; diagnostics products, including blood collection tubes, safety blood collection set, blood collection needles, and standard needle holder. In addition, the company offers transfusion system products, including blood bags, blood administration set, and others; anesthesia and respiratory care products, comprising variable concentration masks, oxygen mask with reservoirs, fixed concentration masks, aerosol therapy masks, ventilator circuits, suction catheters, spinal needle, polyciser, oxygen catheter, nebulizer compressor system, twin bore nasal oxygen cannula mucus extractor, HME filter, oro-pharyngeal airways, endotracheal tubes, catheter mount, and brain circuit; urology products, including urine collection bags, leg bag set, irrigation sets, and foley balloon and urine drainage catheters; wound drainage; and gastroenterology products. The company was incorporated in 1995 and is based in New Delhi, India.
Details
Sector
Healthcare
Industry
Medical Instruments & Supplies
CEO
Mr. Himanshu Baid
Headquarters
New Delhi
Employees
2,614
Website
polymedicure.comExchange
View on NSE ↗Key stats
Market cap
₹16,084.04 Cr
P/E ratio (TTM)
51.1
Dividend yield
0.23%
EPS (TTM)
₹31.06
Beta (1Y · daily vs NIFTY 50)
0.91
Beta (5Y · monthly vs NIFTY 50)
0.91
Shares float
3.63 Cr
EPS · quarter ended Jun 2026
₹8.48
Financial Performance
01 · Financials
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based
05 · Capital Structure & Asset Utilization
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
07 · Debt Level & Coverage
08 · Profit & Loss — as filed
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| ₹804.88 Cr | ₹960.97 Cr | ₹1,151.42 Cr | ₹1,434.54 Cr | ₹1,758.96 Cr | |
| ₹628.14 Cr | ₹768.17 Cr | ₹915.85 Cr | ₹1,092.80 Cr | ₹1,311.62 Cr | |
Profit before tax, and share of net profit from associates | ₹176.74 Cr | ₹192.80 Cr | ₹235.56 Cr | ₹341.74 Cr | ₹447.34 Cr |
Share of profit from associates | ₹3.31 Cr | ₹2.45 Cr | ₹1.93 Cr | ₹2.53 Cr | ₹5.18 Cr |
Profit before tax | ₹180.05 Cr | ₹195.24 Cr | ₹237.49 Cr | ₹344.27 Cr | ₹452.52 Cr |
| ₹44.18 Cr | ₹48.74 Cr | ₹58.21 Cr | ₹86.01 Cr | ₹113.96 Cr | |
Profit after tax | ₹135.87 Cr | ₹146.51 Cr | ₹179.28 Cr | ₹258.26 Cr | ₹338.56 Cr |
Acturial gains/(losses) of defined benefit plan | ₹13.98 L | — | — | — | — |
Re-measurement gains/(losses) of defined benefit plan | — | ₹31.69 L | ₹19.80 L | ₹-1.13 Cr | ₹-2.07 Cr |
Tax impacts on above | ₹-3.52 L | ₹-7.98 L | ₹-4.98 L | ₹28.43 L | ₹52.04 L |
| ₹135.98 Cr | ₹146.43 Cr | ₹179.69 Cr | ₹257.38 Cr | ₹337.20 Cr | |
Equity holders of the parent | ₹135.87 Cr | ₹146.51 Cr | ₹179.28 Cr | ₹258.26 Cr | ₹338.56 Cr |
Equity holders of the parent | ₹135.98 Cr | ₹146.43 Cr | ₹179.69 Cr | ₹257.38 Cr | ₹337.20 Cr |
Basic | 15.25 | 15.28 | 18.69 | 26.92 | 34.13 |
Diluted | 15.24 | 15.27 | 18.67 | 26.90 | 34.11 |
Basic | ₹8.91 Cr | ₹9.59 Cr | ₹9.59 Cr | ₹9.59 Cr | ₹9.92 Cr |
Diluted | ₹8.92 Cr | ₹9.60 Cr | ₹9.60 Cr | ₹9.60 Cr | ₹9.92 Cr |
The company’s own captions, order and figures from its annual reports. A dash means the company printed no figure on that line that year. Each year is read from the latest annual report that carries it and was checked against the headline total shown elsewhere on this page.
All years: consolidated statements.
09 · Balance Sheet — as filed
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| ₹519.62 Cr | ₹593.40 Cr | ₹770.52 Cr | ₹1,017.07 Cr | ₹1,275.46 Cr | |
| ₹1,223.73 Cr | ₹1,376.83 Cr | ₹1,577.21 Cr | ₹1,858.67 Cr | ₹3,192.45 Cr | |
| ₹965.57 Cr | ₹1,087.48 Cr | ₹1,241.63 Cr | ₹1,470.05 Cr | ₹2,765.66 Cr | |
| ₹86.76 Cr | ₹62.68 Cr | ₹42.28 Cr | ₹37.40 Cr | ₹56.63 Cr | |
| ₹1,223.73 Cr | ₹1,376.83 Cr | ₹1,577.21 Cr | ₹1,858.67 Cr | ₹3,192.45 Cr |
The company’s own captions, order and figures from its annual reports. A dash means the company printed no figure on that line that year. Each year is read from the latest annual report that carries it and was checked against the headline total shown elsewhere on this page.
All years: consolidated statements.
10 · Cash Flow Statement — as filed
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
Profit before tax and exceptional items | ₹180.05 Cr | ₹195.24 Cr | ₹237.49 Cr | ₹344.27 Cr | ₹452.52 Cr |
Depreciation and amortisation (Note 31) | ₹47.52 Cr | ₹53.95 Cr | ₹57.17 Cr | ₹63.93 Cr | ₹83.18 Cr |
Share in Income of Associates | ₹-3.31 Cr | ₹-2.45 Cr | ₹-1.93 Cr | ₹-2.53 Cr | ₹-5.18 Cr |
Interest expense | ₹8.51 Cr | ₹4.25 Cr | ₹8.84 Cr | ₹11.30 Cr | ₹12.00 Cr |
Interest income | ₹-3.09 Cr | ₹-1.99 Cr | ₹-5.86 Cr | ₹-12.95 Cr | ₹-13.03 Cr |
Loss/(profit) on sale of Property plant and equipment & investment properties (net) | ₹-72,000 | ₹-53.05 L | ₹-10.03 L | ₹-62.28 L | ₹-12.03 L |
Debts/advances written off | ₹17.99 L | ₹66.06 L | ₹14.22 L | ₹1.18 Cr | ₹33.21 L |
Provision for doubtful debts and advances | ₹29.96 L | ₹3.08 L | ₹59.39 L | ₹1.13 Cr | ₹3.18 Cr |
Credit balances no longer required, written back | ₹-1.67 L | ₹-36.89 L | ₹-21.23 L | ₹-51.36 L | ₹-95.07 L |
Deferred employee compensation expenses (net) | ₹64.73 L | ₹93.10 L | ₹1.93 Cr | ₹2.11 Cr | ₹1.22 Cr |
Unrealised foreign exchange (gain) /loss | ₹10.29 L | ₹-2.88 Cr | ₹-85.74 L | ₹-1.81 Cr | ₹-1.40 Cr |
Other Comprehensive Income | ₹13.98 L | ₹31.69 L | — | — | — |
Ind As Adjustment for Unrealised Gain on Mutual Fund | ₹-3.51 Cr | — | — | — | — |
Ind As Adjustment on Govt. Grant & Subsidy | ₹-1.09 Cr | — | — | — | — |
Ind As Adjustment for Interest Income on Financial Assets | ₹-28.16 L | — | — | — | — |
Ind As Adjustment on Forward Contracts (Net) | ₹-2.16 Cr | — | — | — | — |
Ind As Adjustment for Deferred Processing fees | ₹31.17 L | — | — | — | — |
Ind As Adjustment for Interest on Security Deposit against Rent | ₹3.88 L | — | — | — | — |
Other adjustments including minority | ₹20.31 L | — | — | — | — |
Unrealised (Gain)/Loss on Mutual Fund | — | — | ₹4.01 Cr | ₹-20.95 Cr | ₹-37.73 Cr |
Ind As and other adjustments | — | ₹-12.86 Cr | ₹-2.83 Cr | ₹3.51 Cr | ₹6.86 Cr |
Operating profit before working capital changes | ₹224.54 Cr | ₹234.32 Cr | ₹298.38 Cr | ₹381.04 Cr | ₹487.15 Cr |
Decrease/(increase) in inventories | ₹-14.39 Cr | ₹-41.88 Cr | ₹-40.29 Cr | ₹-12.38 Cr | ₹-64.54 Cr |
Decrease/ (increase) in sundry debtors | ₹-33.23 Cr | ₹-50.74 Cr | ₹-28.80 Cr | ₹-36.69 Cr | ₹-83.75 Cr |
Decrease/(Increase) in financial assets | ₹14.61 L | ₹64.31 L | ₹-13.51 L | ₹-7.32 Cr | ₹3.27 Cr |
Decrease/(Increase) in other assets | ₹-10.42 Cr | ₹-8.67 Cr | ₹-99.10 L | ₹2.60 Cr | ₹-13.77 Cr |
Increase/ (decrease) in trade payables | ₹5.95 L | ₹24.70 Cr | ₹3.77 Cr | ₹3.76 Cr | ₹-7.28 Cr |
Increase/ (decrease) in other financial liabilities | ₹1.06 Cr | ₹1.18 Cr | ₹5.93 Cr | ₹13.58 Cr | ₹9.78 Cr |
Increase/ (decrease) in other liabilities | ₹-3.90 Cr | ₹10.75 Cr | ₹9.77 Cr | ₹-4.46 Cr | ₹59.36 L |
Increase/ (decrease) in provisions | ₹-51.45 L | ₹62.01 L | ₹1.28 Cr | ₹23.95 L | ₹1.39 Cr |
| ₹118.73 Cr | ₹123.47 Cr | ₹191.05 Cr | ₹266.08 Cr | ₹240.42 Cr | |
Cash generated from operations | ₹163.35 Cr | ₹170.93 Cr | ₹248.92 Cr | ₹340.38 Cr | ₹332.83 Cr |
Direct taxes paid (net of refunds) | ₹-44.62 Cr | ₹-47.46 Cr | ₹-57.87 Cr | ₹-74.30 Cr | ₹-92.41 Cr |
| ₹-435.58 Cr | ₹-85.33 Cr | ₹-179.24 Cr | ₹-240.94 Cr | ₹-1,194.28 Cr | |
| ₹316.95 Cr | ₹-35.34 Cr | ₹-12.51 Cr | ₹-20.15 Cr | ₹950.51 Cr | |
| ₹4.95 Cr | ₹7.76 Cr | — | ₹12.05 Cr | ₹8.70 Cr | |
Net increase in cash and cash equivalents (A+B+C) | ₹9.72 L | ₹2.80 Cr | — | ₹4.99 Cr | ₹-3.35 Cr |
Cash and cash equivalents at the beginning of the year | ₹4.86 Cr | ₹4.95 Cr | — | ₹7.06 Cr | ₹12.05 Cr |
| ₹4.95 Cr | ₹7.76 Cr† | — | ₹12.05 Cr | ₹8.70 Cr | |
Cash and cash equivalents at the end of the year as per above | ₹4.95 Cr† | ₹7.76 Cr† | — | ₹12.05 Cr | ₹8.70 Cr |
| — | — | — | ₹153.95 Cr | ₹164.31 Cr |
The company’s own captions, order and figures from its annual reports. A dash means the company printed no figure on that line that year. Each year is read from the latest annual report that carries it and was checked against the headline total shown elsewhere on this page.
† Computed, not printed: that year’s report leaves this figure out, but the lines it does print fix it exactly (hover for the sum). The same relationship holds in every year where all of its lines are printed.
All years: consolidated statements.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21 | Dec 21 | Mar 22 | Jun 22 | Sep 22–Dec 22(2Q) | Mar 23–Jun 23(2Q) | Sep 23–Dec 23(2Q) | Mar 24 | Jun 24 | Aug 24–Sep 24(2Q) | Dec 24–Jun 25(3Q) | Sep 25–Jun 26(4Q) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 44.77% | 44.76% | 44.66% | 53.34% | 53.33% | 53.31% | 53.16% | 53.15% | 66.03% | 62.56% | 62.44% | 62.42% |
| Public | 55.23% | 55.24% | 55.34% | 46.66% | 46.67% | 46.69% | 46.84% | 46.85% | 33.97% | 37.44% | 37.56% | 37.58% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.25 L Cr | ₹1,769.9 | 38.8 | 5.09 | 13.7% | 0.06 | +11.9% | +3.7% |
| Divi's Laboratories Limited | ₹2.66 L Cr | ₹10,037.5 | 90.8 | 15.85 | 15.3% | 0.00 | +12.3% | +47.5% |
| Torrent Pharmaceuticals Limited | ₹1.79 L Cr | ₹4,738.5 | 79.4 | 21.31 | 25.8% | 1.79 | +21.5% | +32.5% |
| Laurus Labs Limited | ₹1.27 L Cr | ₹2,348 | 94.8 | 23.94 | 16.8% | 0.48 | +22.0% | +146.2% |
| Apollo Hospitals Enterprise Limited | ₹1.23 L Cr | ₹8,599.5 | 58.8 | 12.95 | 20.5% | 0.90 | +15.7% | +10.1% |
| Zydus Lifesciences Limited | ₹1.19 L Cr | ₹1,188.1 | 26.7 | 4.40 | 18.6% | 0.46 | +18.4% | +22.3% |
| Lenskart Solutions Limited | ₹1.16 L Cr | ₹689.7 | 181.4 | 13.30 | 5.6% | 0.35 | +35.4% | — |
| Dr. Reddy's Laboratories Limited | ₹1.14 L Cr | ₹1,374 | 40.6 | 3.02 | 11.4% | 0.21 | +3.2% | +14.5% |
| Cipla Limited | ₹1.13 L Cr | ₹1,402 | 38.9 | 3.27 | 11.3% | 0.02 | +2.1% | -6.7% |
| Mankind Pharma Limited | ₹1.03 L Cr | ₹2,475 | 45.9 | 6.31 | 11.7% | 0.39 | +17.0% | +3.1% |
| Aurobindo Pharma Limited | ₹98,101.93 Cr | ₹1,705 | 26.6 | 2.59 | 9.2% | 0.21 | +6.4% | +48.4% |
| Poly Medicure Limited | ₹14,971.09 Cr | ₹1,496.2 | 47.6 | 4.82 | 10.4% | 0.11 | +12.4% | -21.9% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Index membership
5 indices